Oppenheimer has revised its price target for Jasper Therapeutics (JSPR, Financial) from $80 to $65 while maintaining an Outperform rating. This adjustment follows the company's quarterly results. A significant development is Jasper's plan to expedite updates from the BEACON CSU study, now expected in the first half of the third quarter, earlier than the previously anticipated mid-2025 timeline, marking a crucial catalyst for the stock.
Further, Jasper aims to release new data from the SPOTLIGHT CIndU study at the EAACI conference. Additionally, Oppenheimer notes that the initial findings from the ETESIAN Phase 1b/2a allergen challenge study are proceeding as planned, with results anticipated in the latter half of the year as patient enrollment progresses.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $47.88 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies an upside of 887.11% from the current price of $4.85. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
